Next generation electronics enhance reliability and efficiency while reducing power consumption and operating costs
INDIANAPOLIS – (May 13, 2026) – Beckman Coulter Life Sciences, a Danaher company and global leader in laboratory automation and innovation, today announced the commercial release of the Echo 650 Plus Series Acoustic Liquid Handlers—introducing next generation electronics, enhanced acoustic performance, and a 54% reduction in power consumption to increase reliability, lower operating costs, and support sustainability goals in high-throughput laboratories.
“With the Echo 650 Plus Series, we focused on delivering measurable performance improvements that matter to our customers—greater reliability, lower operating costs, and smarter, real-time system intelligence,” said Sudarshana Seshadri, Vice President Product Management, Beckman Coulter Life Sciences. “These upgrades empower scientists to scale acoustic liquid handling with confidence, efficiency, and precision across demanding workflows.”
The Echo 650 Plus Series features a Next Generation Transducer (NGT) with a durable titanium lens that enables simplified instrument power-down and reliable, rapid recovery while reducing routine maintenance. Enhanced transducer stability eliminates the need for routine focus calibration tracking and adjustments, minimizing hands-on intervention and maximizing system uptime.
New electronics architecture further enhances system performance, improving real-time computational capability, manufacturability and overall reliability. Together, these advancements deliver a 54% reduction in power consumption compared to legacy Echo systems—supporting lower operating costs and sustainability initiatives. These advances reflect Beckman Coulter Life Sciences application of Danaher’s continuous improvement and innovation principles to deliver measurable performance gains at scale.
The enhanced real-time processing capabilities of the Echo 650 Plus Series instruments enable Dynamic Fluid Analysis 2* (DFA2), which uses machine learning-driven models and real-time acoustic feedback to optimize Acoustic Droplet Ejection (ADE) performance. DFA2 automatically accounts for natural variability in source plate manufacturing and dynamically evaluates fluid surface response prior to each droplet ejection, selecting the optimal ADE calibration for every well. This intelligent, adaptive approach improves fluid measurement accuracy, transfer reliability, and long-term consistency across a wide range of sample types.
The Echo 650 Plus Series is built on commercially proven acoustic liquid handling technology and is engineered to support demanding drug discovery applications.
Learn more about Echo 650 Plus at https://www.beckman.com/liquid-handlers/echo-acoustic/echo-650-plus-series.
*Plate- and calibration-dependent.
Products and applications are not intended or validated for use in diagnostic procedures.
About Beckman Coulter Life Sciences
Time is the most critical facet in the laboratory today: time to get life-saving therapies to patients faster; reclaiming time by automating tedious manual workflows; and saving time otherwise spent addressing erroneous or complex results.
At Beckman Coulter Life Sciences, a Danaher company, we are partners in time. We accelerate answers to critical questions through the power of efficiency, saving hours from some workflows and delivering reliable results in centrifugation, flow cytometry, genomic solutions, particle analysis/counters, and liquid handlers.
We develop innovations for scientists by scientists, with many of our 3,300+ global colleagues coming from the laboratory with a deep understanding of today’s challenges and complexities. We’re passionate about translating science in partnership with our customers, and our customizable, accessible and sustainable solutions empower them with intuitive workflow efficiencies.
Time and again customers put their trust in us, with 400,000+ of our built-to-last products currently delivering results in labs worldwide—all backed by our dependable service and application experts offering educational insights and tailored support.
It’s all part of our time-tested approach since 1935 to bring meaningful innovations at the speed of life—and we’re just beginning. Working together, let’s advance human health for a better tomorrow!
Get to know us by clicking here and by following us on LinkedIn.
About Danaher
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them. Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com.
Media Contact:
Amber Smock,
Marketing Communications Manager
[email protected]
2026-GBL-EN-109722-v1
